Quarterly Result12 Aug 2026, 12:33 pm
Marksans Pharma Q1 FY27: Record Profitability, Cash Crosses ₹1,000 Cr
AI Summary
Marksans Pharma Ltd. reported record financial results for Q1 FY27, with EBITDA soaring 113% YoY to ₹213 crore and PAT growing 174% YoY to ₹159 crore. The company achieved an all-time high quarterly revenue of ₹356 crore in the UK & Europe region, driven by strong market share gains and new launches. Europe is highlighted as a significant growth engine, boosted by the acquisition of QliniQ. Consolidated operating revenue increased by 35.6% YoY to ₹841 crore. The company also crossed ₹1,000 crore in cash balance for the first time, ending the quarter at ₹1,058 crore, demonstrating strong financial health and flexibility for future investments.
Key Highlights
- Q1 FY27 EBITDA up 113% YoY to ₹213 Cr; PAT up 174% YoY to ₹159 Cr.
- UK & Europe revenue hit record ₹356 Cr, up 74.7% YoY.
- Consolidated revenue grew 35.6% YoY to ₹841 Cr.
- Cash balance exceeded ₹1,000 Cr for the first time, reaching ₹1,058 Cr.
- Acquisitions of QliniQ and ABCnow completed in Europe.
Price Impact
More from MARKSANS